Mette M. Steiniche

Mette M. Steiniche

Auto-generated profile, based on publicly available information

Mette M. Steiniche

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
MSMette M. Steiniche
Mette M. Steiniche
SLSidsel Christy Lindgaard
Sidsel Christy Lindgaard
ICInna Markovna Markovna Chen
Inna Markovna Markovna Chen
JJJulia Sidenius Johansen
Julia Sidenius Johansen
RARikke Andersen
Rikke Andersen
KSKaren-Lise Spindler
Karen-Lise Spindler
Purpose: Changes in ctDNA levels during systemic treatment may predict treatment efficacy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), but quantitative response criteria are not yet established. This study evaluates our recently proposed ctDNA-RECIST. Experimental Design: Blood samples were collected before treatment, before the second treatment cycle, and at the time of the first CT evaluation from 220 patients with metastatic PDAC receiving first-line palliative chemotherapy. Plasma ctDNA levels were measured using Droplet Digital PCR with HOXA9 methylation assays. ctDNA response was determined according to ctDNA-RECIST and correlated with overall survival (OS). Results: ctDNA was positive before treatment in 71% of the patients and was related to OS [HR = 1.61; 95% confidence interval (CI), 1.19–2.19; P = 0.002]. Among ctDNA-positive patients, ctDNA maximal response (MR; n = 41) and ctDNA disease control (DC; n = 107) before the second treatment cycle had longer OS compared with ctDNA progressive disease (PD; n = 5; median OS: MR 11.9 months, DC 7.2 months, PD 3.6 months; P = 0.002). In Cox regression, ctDNA DC (HR = 1.55; 95% CI, 1.07–2.26; P = 0.021) and ctDNA PD (HR = 4.50; 95% CI, 1.74–11.6; P = 0.002) showed shorter OS compared with ctDNA MR. The same applied to ctDNA response at the time of the first CT evaluation assessed from the second treatment cycle (P < 0.001) and from treatment start (P < 0.001). Conclusions: ctDNA-RECIST applied to liquid biopsies holds potential for early evaluation of treatment benefit in patients with metastatic PDAC, offering a novel, minimally invasive method to guide early clinical decision-making. Future studies should validate ctDNA-RECIST prospectively, preferably in randomized controlled trials.

30 October 2025 in The Journal of Liquid Biopsy
Verified
Journal Article
Open access
MSMette M. Steiniche
Mette M. Steiniche
LCLouise B. Callesen
Louise B. Callesen
EVElizabeth H. Vlk
Elizabeth H. Vlk
LVLise Ventzel
Lise Ventzel
STSigne Timm
Signe Timm
KSKaren-Lise G. Spindler
Karen-Lise G. Spindler
This systematic review and meta-analysis synthesised current evidence on circulating tumour DNA (ctDNA) for predicting clinical outcomes in patients with non-resectable pancreatic ductal adenocarcinoma (PDAC). PubMed, Embase, and Cochrane databases were searched up to 31/01/2025. Eligible studies reported prognostic value of ctDNA in patients with non-resectable PDAC. Meta-analyses evaluated associations between baseline ctDNA and changes in ctDNA during treatment (ctDNA kinetics) and survival outcomes. Risk of bias was assessed using the Quality in Prognosis Studies (QUIPS) tool. Sixty-four studies involving 5652 patients with non-resectable PDAC were included, with 24 studies contributing to meta-analyses. High baseline ctDNA level implied shorter overall survival (OS; HR = 2.3, 95 % CI 1.9–2.8; n = 1883) and progression-free survival (PFS; HR = 2.1, 95 % CI 1.8–2.4; n = 1196). Unfavourable ctDNA kinetics were associated with shorter OS (HR = 3.1, 95 % CI 2.3–4.3; n = 269) and PFS (HR = 4.3, 95 % CI 2.6–7.2; n = 244). Thirty-three studies had high risk of bias in at least one QUIPS domain. Baseline ctDNA and ctDNA kinetics demonstrate strong prognostic value in non-resectable PDAC. However, clinical translation is limited by methodological heterogeneity, notably the use of study-specific, non-validated thresholds. Standardised, externally validated thresholds for interpreting ctDNA changes are needed to support clinical implementation. CRD42023438774.

14 November 2025
Verified
Other
Open access
MSMette M. Steiniche
Mette M. Steiniche
SLSidsel Christy Lindgaard
Sidsel Christy Lindgaard
ICInna Markovna Markovna Chen
Inna Markovna Markovna Chen
JJJulia Sidenius Johansen
Julia Sidenius Johansen
RARikke Andersen
Rikke Andersen
KSKaren-Lise Spindler
Karen-Lise Spindler
Description of the quality control of DNA extraction

14 November 2025
Verified
Other
Open access
MSMette M. Steiniche
Mette M. Steiniche
SLSidsel Christy Lindgaard
Sidsel Christy Lindgaard
ICInna Markovna Markovna Chen
Inna Markovna Markovna Chen
JJJulia Sidenius Johansen
Julia Sidenius Johansen
RARikke Andersen
Rikke Andersen
KSKaren-Lise Spindler
Karen-Lise Spindler
Overall survival by ctDNA response and treatment regimen.

14 November 2025
Verified
Other
Open access
MSMette M. Steiniche
Mette M. Steiniche
SLSidsel Christy Lindgaard
Sidsel Christy Lindgaard
ICInna Markovna Markovna Chen
Inna Markovna Markovna Chen
JJJulia Sidenius Johansen
Julia Sidenius Johansen
RARikke Andersen
Rikke Andersen
KSKaren-Lise Spindler
Karen-Lise Spindler
REMARK checklist of reported items

14 November 2025
Verified
Other
Open access
MSMette M. Steiniche
Mette M. Steiniche
SLSidsel Christy Lindgaard
Sidsel Christy Lindgaard
ICInna Markovna Markovna Chen
Inna Markovna Markovna Chen
JJJulia Sidenius Johansen
Julia Sidenius Johansen
RARikke Andersen
Rikke Andersen
KSKaren-Lise Spindler
Karen-Lise Spindler
Purpose:Changes in ctDNA levels during systemic treatment may predict treatment efficacy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), but quantitative response criteria are not yet established. This study evaluates our recently proposed ctDNA-RECIST.Experimental Design:Blood samples were collected before treatment, before the second treatment cycle, and at the time of the first CT evaluation from 220 patients with metastatic PDAC receiving first-line palliative chemotherapy. Plasma ctDNA levels were measured using Droplet Digital PCR with HOXA9 methylation assays. ctDNA response was determined according to ctDNA-RECIST and correlated with overall survival (OS).Results:ctDNA was positive before treatment in 71% of the patients and was related to OS [HR = 1.61; 95% confidence interval (CI), 1.19–2.19; P = 0.002]. Among ctDNA-positive patients, ctDNA maximal response (MR; n = 41) and ctDNA disease control (DC; n = 107) before the second treatment cycle had longer OS compared with ctDNA progressive disease (PD; n = 5; median OS: MR 11.9 months, DC 7.2 months, PD 3.6 months; P = 0.002). In Cox regression, ctDNA DC (HR = 1.55; 95% CI, 1.07–2.26; P = 0.021) and ctDNA PD (HR = 4.50; 95% CI, 1.74–11.6; P = 0.002) showed shorter OS compared with ctDNA MR. The same applied to ctDNA response at the time of the first CT evaluation assessed from the second treatment cycle (P < 0.001) and from treatment start (P < 0.001).Conclusions:ctDNA-RECIST applied to liquid biopsies holds potential for early evaluation of treatment benefit in patients with metastatic PDAC, offering a novel, minimally invasive method to guide early clinical decision-making. Future studies should validate ctDNA-RECIST prospectively, preferably in randomized controlled trials.